Conclusion: Evidence from trials and observational studies suggest that treatment retention is better for methadone than for sublingual buprenorphine. Comparative evidence on other outcomes examined showed few statistically significant differences and was generally based on small numbers of studies. These findings highlight the imperative for interventions to improve retention, consideration of client-centred factors (such as client preference) when selecting between methadone and buprenorphine, and harmonisation of data collection and reporting to strengthen future syntheses.
PubMed 37167985 ↗Buprenorphine
Also known as Suboxone, Subutex
The short answer. There isn't much data on Buprenorphine yet — 17 mentions, 6 with a clear outcome — so treat these numbers as anecdotal. It is well studied — 339 meta-analyses on PubMed.
From 17 mentions in total — the rest didn't say how it went and aren't counted.
What Buprenorphine does, according to users
Of the people who reported each effect, the share who said it got better.
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 339 meta-analyses on PubMed ↗ · 1,008 randomized trials ↗
Conclusion: Based on our analysis, patients using <20 g of kratom/d could be initiated on opioid agonist therapy with 4/1 mg-8/2 mg buprenorphine-naloxone/d, while patients using kratom doses >40 g/d could be initiated with 12/3 mg-16/4 mg of buprenorphine-naloxone/day.
PubMed 32858563 ↗Conclusion: Overall 26 RCTs involving 848 dogs were included. Tramadol administration probably results in a lower need for rescue analgesia versus no treatment or placebo [moderate CoE; relative risk (RR): 0.47; 95% confidence interval (CI): 0.26-0.85; I2 = 0%], and may result in a lower need for rescue analgesia versus buprenorphine (low CoE; RR: 0.50; 95% CI: 0.20-1.24), codeine (low CoE; RR: 0.75; 95% CI: 0.16-3.41) and nalbuphine (low CoE; RR: 0.05; 95% CI: 0.00-0.72). However, tramadol administration may result in an increased requirement for rescue analgesia versus methadone (low CoE; RR: 3.45; 95%
PubMed 33745825 ↗Conclusion: The induction phase onto methadone treatment and the time immediately after leaving treatment with both drugs are periods of particularly increased mortality risk, which should be dealt with by both public health and clinical strategies to mitigate such risk. These findings are potentially important, but further research must be conducted to properly account for potential confounding and selection bias in comparisons of mortality risk between opioid substitution treatments, as well as throughout periods in and out of each treatment.
PubMed 28446428 ↗778 human trials on ClinicalTrials.gov test Buprenorphine — 480 completed, 83 recruiting now. See all on ClinicalTrials.gov ↗
- STAMPS: South Carolina Buprenorphine Treatment Initiation, Adherence, and Retention Utilizing Mobile Health Units and Peer Support Specialists · Opioid Use Disorder · 2025
- tAN for PTSD and OUD in Buprenorphine Therapy · Posttraumatic Stress Disorder, Opioid Use Disorder · 2026
- MHealth Incentivized Adherence Plus Patient Navigation · Opioid Use Disorder, Medication Adherence · 2025
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
Buprenorphine is a Schedule III controlled substance in the US. DEA controlled-substance list ↗
Boxed warning (the FDA's strongest label warning): “RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and…”
31 recalls of products named for Buprenorphine. Most recent:
- 2026-09-09 · Class III: Labeling: Label Mix-up record ↗
- 2026-06-24 · Class II: Crystallization; identified as Buprenorphine free base record ↗
- 2026-05-20 · Class II: Crystallization; identified as Buprenorphine free base record ↗
Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗
99,861 adverse-event reports mention Buprenorphine. Most often reported:
- Death · 13,812
- Drug dependence · 12,594
- Overdose · 12,419
- Toxicity to various agents · 10,954
- Pain · 8,560
- Drug withdrawal syndrome · 7,132
Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗
LiverTox rates Buprenorphine B — a highly likely cause of liver injury (12–50 published cases). LiverTox entry ↗
NIH has funded 247 research projects with Buprenorphine in the title, $326,920,393 in total (1985–2026). NIH RePORTER ↗
Plain-language guides from the US government: MedlinePlus: Buprenorphine Buccal (chronic pain) ↗
Dosage people report
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“it was beneficial to quit buprenorphine, which I did on 5/13/16.”
“I did a year of Subutex so I doubt any opiates would work for me anymore.”
“Suboxone and bupropion has shown to help those with meth addiction...I took this combination it killed my cravings for stims”
“But I'm not addicted to them anymore (subutex)”
Buprenorphine compared
Other options for anxiety
Sources
- User reports: 17 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- FDA drug label (DailyMed) ↗
- FDA adverse-event reports (FAERS) ↗
- FDA recalls ↗
- US DEA ↗
- LiverTox (NIH) ↗
- MedlinePlus (NIH) ↗
- NIH RePORTER ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate